Atea Pharmaceuticals (AVIR) Preferred Stock Liabilities (2019 - 2020)
Atea Pharmaceuticals (AVIR) recorded quarterly Preferred Stock Liabilities of $175.7 million in Q3 2020, little changed quarter-over-quarter from $175.7 million in Q2 2020, and up 154.28% on a YoY basis from $69.1 million in Q4 2019.
Atea Pharmaceuticals (AVIR) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Atea Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $175.7 million for Q3 2020.
- In Q3 2020, Preferred Stock Liabilities rose 154.28% year-over-year to $175.7 million; the TTM figure through Sep 2020 stood at $175.7 million (up 154.28% YoY), while the FY2019 annual figure was $69.1 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was $175.7 million for Q3 2020 at Atea Pharmaceuticals, roughly flat from $175.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $175.7 million in Q2 2020 to a low of $69.1 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 175.75 Mn |
| Jun 30, 2020 | 175.75 Mn |
| Mar 31, 2020 | 69.11 Mn |
| Dec 31, 2019 | 69.11 Mn |
| Sep 30, 2019 | 69.11 Mn |